[{"address1": "188 East Blaine Street", "address2": "Suite 200", "city": "Seattle", "state": "WA", "zip": "98102", "country": "United States", "phone": "206 788 4545", "website": "https://www.alpineimmunesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 142, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mitchell H. Gold M.D.", "age": 55, "title": "Executive Chairman & CEO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 778200, "exercisedValue": 0, "unexercisedValue": 3826649}, {"maxAge": 1, "name": "Dr. Stanford  Peng M.D., Ph.D.", "age": 52, "title": "President and Head of Research & Development", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 751200, "exercisedValue": 0, "unexercisedValue": 1979010}, {"maxAge": 1, "name": "Mr. Paul  Rickey", "age": 44, "title": "Senior VP, CFO, Treasurer & Secretary", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": 577100, "exercisedValue": 0, "unexercisedValue": 540467}, {"maxAge": 1, "name": "Mr. Ulrich Martin Fuhs", "age": 55, "title": "VP of Finance & Chief Accounting Officer", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. M. Christina Yi", "age": 46, "title": "Chief Technology Officer", "yearBorn": 1977, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Greenblatt", "title": "Director of Investor Relations & Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Remy  Durand Ph.D.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1986, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wolfgang  Dummer M.D., Ph.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 64.55, "open": 64.54, "dayLow": 64.445, "dayHigh": 64.58, "regularMarketPreviousClose": 64.55, "regularMarketOpen": 64.54, "regularMarketDayLow": 64.445, "regularMarketDayHigh": 64.58, "beta": 1.165, "forwardPE": -34.16931, "volume": 1793687, "regularMarketVolume": 1793687, "averageVolume": 2249303, "averageVolume10days": 6951080, "averageDailyVolume10Day": 6951080, "bid": 64.52, "ask": 64.6, "bidSize": 200, "askSize": 200, "marketCap": 4233897216, "fiftyTwoWeekLow": 6.71, "fiftyTwoWeekHigh": 64.58, "priceToSalesTrailing12Months": 71.91211, "fiftyDayAverage": 40.5488, "twoHundredDayAverage": 21.236925, "currency": "USD", "enterpriseValue": 3915471360, "profitMargins": -0.54664004, "floatShares": 44931221, "sharesOutstanding": 65560500, "sharesShort": 5284601, "sharesShortPriorMonth": 4427533, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0806, "heldPercentInsiders": 0.04645, "heldPercentInstitutions": 0.91443, "shortRatio": 4.15, "shortPercentOfFloat": 0.1314, "impliedSharesOutstanding": 65560500, "bookValue": 5.434, "priceToBook": 11.884432, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -32184000, "trailingEps": -0.64, "forwardEps": -1.89, "lastSplitFactor": "1:4", "lastSplitDate": 1500940800, "enterpriseToRevenue": 66.504, "enterpriseToEbitda": -89.652, "52WeekChange": 8.1086035, "SandP52WeekChange": 0.23061275, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ALPN", "underlyingSymbol": "ALPN", "shortName": "Alpine Immune Sciences, Inc.", "longName": "Alpine Immune Sciences, Inc.", "firstTradeDateEpochUtc": 1434547800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e994e1f0-358a-395f-b1e2-8dc3a2a1a651", "messageBoardId": "finmb_283828497", "gmtOffSetMilliseconds": -14400000, "currentPrice": 64.58, "targetHighPrice": 65.0, "targetLowPrice": 44.0, "targetMeanPrice": 62.0, "targetMedianPrice": 65.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 327412000, "totalCashPerShare": 4.995, "ebitda": -43674000, "totalDebt": 9914000, "quickRatio": 7.817, "currentRatio": 7.862, "totalRevenue": 58876000, "debtToEquity": 3.023, "revenuePerShare": 1.178, "returnOnAssets": -0.08298001, "returnOnEquity": -0.12687, "freeCashflow": -29060500, "operatingCashflow": -79012000, "revenueGrowth": 10.114, "grossMargins": -0.37414002, "ebitdaMargins": -0.7418, "operatingMargins": 0.05014, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-23"}]